SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Progyny (PGNY) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates

Progyny (PGNY) delivered earnings and revenue surprises of +1.96% and +0.45%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?

Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PGNY or CRL: Which Is the Better Value Stock Right Now?

PGNY vs. CRL: Which Stock Is the Better Value Option?

Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?

Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's  What You Should Know

The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns

MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks

 IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

• Reported GAAP EPS of $0.52 up 15.56% YoY
• Reported revenue of $341.25M up 8.90% YoY
• Progyny raised the midpoint of Full Year 2026 guidance: revenue is projected at $1.37B to $1.39B, net income at $107M to $110.6M, and Adjusted EBITDA at $235M to $240M.

Progyny's Adjusted EBITDA margin was 17.1% versus 17.5%; a large client did not renew, and cash, cash equivalents and marketable securities decreased $41.3M from June 30, 2026.

Progyny added 1.3M new covered lives and over 85 clients with near 100% retention for 2027, reported increased gross profit and gross margin, and cited strong demand for more comprehensive coverage and newest services.

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Progyny Inc

Progyny Stock Logs Best Day In 2 Months As BofA Calls Trump IVF Policy ‘Incremental Positive’ — Traders Eye More Upside

Equity

Bullish Sentiment

Shares of Progyny logged their best session in two months on Thursday after BofA Securities reiterated a ‘Buy’ rating and $30 price target, calling the forthcoming White House initiative to expand access to in-vitro fertilization (IVF) an “incremental positive” for the company.<a href="https://stocktwits.com/symbol/PGNY">Progyny’s stock</a> surged 5% to close at $21.33 on Thursday, marking their highest levels in over a month, before slipping 0.7% in after-hours trading.BofA Securities’ TakeBofA Securities said the actual impact may be “more nuanced.” The firm said the spotlight around IVF is a positive for awareness and may drive some demand for coverage in certain pockets of employers.&nbsp;Given Progyny is a “market leader” with broad geographic coverage, BofA Securities said the company appears well-positioned to capture upside if there is, in fact, a benefit to coverage and utilization.Policy BackdropU.S. President Donald Trump is set to unveil measures to expand IVF access. Earlier Thursday, the administration announced a deal with Merck KGaA under which its U.S. arm EMD Serono will sell fertility drugs Gonal-f, Ovidrel, and Cetrotide directly to consumers, with a combined 84% discount when all three are used in an IVF cycle, alongside tariff relief arrangements, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/white-house-set-announce-proposal-seeking-make-ivf-more-accessible-nyt-reports-2025-10-16/">report</a>.Trump also outlined plans to make it legal for companies to offer supplemental insurance for fertility care and to issue guidance encouraging employer IVF coverage, with estimated savings of $2,200 per cycle. IVF typically costs $12,000–$25,000 per cycle in the U.S.Stocktwits Traders Turn Bullish On Progyny After IVF NewsOn Stocktwits, retail sentiment for Progyny was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:967/127;" src="https://news.stocktwits-cdn.com/pgny_st_meter_jpg_a5b3ccbd69.webp" alt="pgny st meter.jpg" width="967" height="127"><figcaption>PGNY sentiment and message volume as of October 16 | Source: Stocktwits</figcaption></figure>One retail trader predicted Progyny’s after-hours surge on Thursday in advance and said it will also move higher into the next trading day, urging others to buy before it’s “too late.”&nbsp;<stembedurl>https://stocktwits.com/JrNannies/message/632648094</stembedurl>Another user noted that Progyny is directly linked to news on carve-outs and supplemental insurance, unlike other IVF-related stocks that&nbsp;rallied simply on name association.<stembedurl>https://stocktwits.com/thegreatone/message/632647572</stembedurl>Progyny’s stock has risen 24% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Progyny’s stock (PGNY) has risen 24% so far in 2025. (Photo credit: Getty Images)

Trump may potentially announce new measures to expand access to in-vitro fertilization, including guidance for employers to offer supplemental fertility insurance and steep discounts on key IVF drugs.

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$35.77
Prev Close	$34.84
Open	$35.00
Dividend Yield	0.00%
50-Day Moving Average	$27.45
Beta	0.36
Avg. Volume	971,106.82
PE Ratio	31.95

52-Week High	$35.50
52-Week Low	$16.10
Market Capitalization	$2.57B
EPS (Annual)	$0.6512
Price to Book	6.29
Revenue Per Employee	$1.51M

Feed

News

Sentiment

Earnings

Fundamentals

Info

PGNY Fundamentals